BridgeBio Rises 6.8% on BBP-418 Data, Neutral Rating Set with $74 Target
BridgeBio Pharma shares rose 6.8% to $68.05 on heavy volume after positive late-stage BBP-418 trial results showed limb-girdle muscular dystrophy improvements supporting a H1 2026 NDA submission. Initiated at Neutral with a $74 target, analysts cited rapid Attruby uptake for ATTR-CM, 2025 cash balance and pipeline optionality offset by regulatory and commercial risks.
1. Stock Surge Fueled by BBP-418 Data
BridgeBio Pharma shares rose 6.8% to $68.05 on heavy volume after positive late-stage BBP-418 trial results. The data demonstrated meaningful functional improvements in limb-girdle muscular dystrophy patients and underpinned plans to submit a New Drug Application in H1 2026.
2. Neutral Rating Highlights Balanced Outlook
Analysts initiated coverage with a Neutral rating and a $74 price target, highlighting rapid uptake of Attruby for ATTR-CM and a robust unaudited cash position at year-end 2025. They warned that commercial sustainability, pricing durability and regulatory hurdles for pipeline assets such as encaleret and BBP-418 could limit near-term upside.